Purpose:To investigate the efficacy of intraocular pressure (IOP) control and medication use over time after trabeculectomy (TRBC) and Ex-PRESS shunt implantation in primary-open-angle-glaucoma (POAG) patients.Design:Retrospective case series.Patients and methods:A total of 33 unilateral POAG patients were enrolled, and 17 patients received traditional TRBC and 16 patients received Ex-PRESS device implantation. Data on IOP, reduction of antiglaucoma medication, and major complications were collected and analyzed after 12 months of follow up.Results:After 12 months of follow up, both groups showed good IOP control. The mean preoperative IOP decreased from 38.5 (±6.9) to 18.2 (±11) mmHg after TRBC, and from 38.5 (±9.1) to 19.53 (±12.36) mmHg after Ex-PRESS implantation (both p < 0.05). The mean number of antiglaucoma medications prescribed at the last follow up decreased from 3.2 (±0.5) preoperatively to 1.2 (±1.4) after TRBC versus 3.3 (±0.7) preoperatively to 1 (±0.9) after Ex-PRESS implantation (both p < 0.05). Complete success rate (defined as no medication after surgery with IOP >5 and <18 mmHg) and qualified success rate (defined as with or without medication after surgery with IOP >5 and <18 mmHg) were similar (47% vs. 43% and 76.47% vs. 75%) between the two groups without statistical difference (p > 0.05). However, postoperative hypotony rate was more frequent after Ex-PRESS (37.5%) than after TRBC (17.64%).Discussion:TRBC and Ex-PRESS implantation provided similar IOP control and reduction of postoperative medication with low incidence of postoperative complications at intermediate-term follow up. However, the Ex-PRESS implantation device may last longer but with extra costs. It is up to the surgeon to decide which procedure to use according to the patient's situation and economic circumstances.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.